Voyager Therapeutics Appoints Neuroscience Expert Steven Hyman, M.D., to Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Steven Hyman, M.D., to its board of directors. Dr. Hyman is a renowned leader in neuroscience with more than 20 years of scientific leadership experience. “We are excited to welcome Steve to Voyager’s board of directors,” said Steven Paul, M.D., president and CEO of Voyager Therapeutics. “He is an extraordinary scientific leader whose expertise in neuroscience and passion for advancing new medicines will be invaluable as Voyager develops its pipeline of gene therapies for patients with severe CNS diseases.” Dr. Hyman has served as director of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT and as a…


Link to Full Article: Voyager Therapeutics Appoints Neuroscience Expert Steven Hyman, M.D., to Board of Directors